Karl Kieburtz
President, Clintrex Research Corporation · University of Rochester Medicine
Credentials: · · ·
History
Research
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
Systematic review or meta-analysis · Neurology · 2007 · 1,704 citations
Levodopa and the progression of Parkinson's disease
New England Journal of Medicine · 2004 · 1,358 citations
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease
New England Journal of Medicine · 2014 · 1,289 citations
47 papers
- KM
36 papers
- IS
35 papers
- CO
33 papers
33 papers
30 papers
- LC
27 papers
23 papers
Grants
- 2018–2025
Morris K. Udall Center at the University of Rochester (UR-Udall Center)
National Institute of Neurological Disorders and Stroke · P50
Project lead · $912.8K · University of Rochester
- 2001–2016
Neuroprotection Studies in PD: A Coordinating Center.
National Institute of Neurological Disorders and Stroke · U01
Contact PI · $24.2M · University of Rochester
- 2006–2016
The University of Rochester's Clinical and Translational Science Institute
National Center for Advancing Translational Sciences · UL1
Contact PI · $10.7M · University of Rochester
- 2006–2016
The University of Rochester Clinical and Translational Science Institute
National Center for Advancing Translational Sciences · KL2
Contact PI · $1.3M · University of Rochester
Clinical trials
- 2009–2012
Bioavailability of Ubiquinol in Huntington Disease
Principal investigator · Completed · Phase 1
University of Rochester
- 2008–2015
Coenzyme Q10 in Huntington's Disease (HD)
Principal investigator · Terminated · Phase 3
Massachusetts General Hospital
- 2007–2008
A Study of the Novel Drug Dimebon in Patients With Huntington's Disease
Principal investigator · Completed · Phase 2
Medivation, Inc.
- 2007–2014
NET-PD LS-1 Creatine in Parkinson's Disease
Principal investigator · Terminated · Phase 3
University of Rochester